Contact this trialFirst, we need to learn more about you.
Peptide
RLS-0071 for Hypoxic-Ischemic Encephalopathy
Recruiting0 awardsPhase 2
San Diego, California
This trial studies a new drug to treat hypoxic-ischemic encephalopathy, a condition that affects 4-12k US people each year, and has a high mortality rate. It will evaluate safety and tolerability in newborns with moderate-severe HIE.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service